Doctor of Podiatric Medicine Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Waybrun Hebert

Podiatrist, Foot & Ankle Surgery Houma, LA Doctor of Podiatric Medicine

NPI 1336133008 CMS profile 332998

1025 W Tunnel Blvd, Ste. B, Houma, LA 70360

Open in the dashboard

General payments

$1,275

33 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Waybrun Hebert of Houma, LA is reported in the CMS Open Payments database as having received $1,275 across 33 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 35th percentile of Podiatrist, Foot & Ankle Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $27 1
2023 General $18 1
2022 General $179 9
2021 General $40 2
2020 General $87 5
2019 General $924 15

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Waybrun Hebert
  • Podiatrist, Foot & Ankle Surgery median
  • Middle half of Podiatrist, Foot & Ankle Surgery
  • National median

In program year 2025, general payments to Waybrun Hebert were reported at $0. Among 6,994 Podiatrist, Foot & Ankle Surgery profiles paid that year, the median was $424 and the middle half received between $139 and $1,306.

Show as a table
Year Waybrun Hebert Podiatrist, Foot & Ankle Surgery median Middle half National median
2019 $924 $389 $118–$1,406 $163
2020 $87 $191 $62–$691 $114
2021 $40 $329 $104–$1,341 $132
2022 $179 $419 $125–$1,611 $149
2023 $18 $377 $128–$1,164 $160
2024 $27 $394 $134–$1,168 $164
2025 $0 $424 $139–$1,306 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Crossroads Extremity Systems, LLC $674 6 payments
  2. Smith+Nephew, Inc. $180 11 payments
  3. Boston Scientific Corporation $86 1 payment
  4. Paratek Pharmaceuticals, Inc. $72 4 payments
  5. Organogenesis Inc. $63 2 payments
  6. GRT US Holding, Inc. $48 2 payments
  7. Zyla Life Sciences $31 2 payments
  8. Stryker Corporation $30 1 payment
  9. Medtronic, Inc. $29 1 payment
  10. KCI USA, Inc $25 1 payment
  11. Other $37 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $1,275 33 payments
Products named General payments · program years 2019–2024
  1. Santyl $87 6 payments
  2. GENERAL VASCULAR INTERVENTION $86 1 payment
  3. COLLAGENASE SANTYL $75 4 payments
  4. NUZYRA $72 4 payments
  5. REGRANEX Pharma Product $71 5 payments
  6. Apligraf $48 1 payment
  7. Qutenza $48 2 payments
  8. REGRANEX Pharma Products $36 2 payments
  9. SPRIX $31 2 payments
  10. ASNIS $30 1 payment
  11. Other $148 7 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

166

Median for Podiatry: 160

Drug cost

$3,915

Median for Podiatry: $2,368

Branded share of claims

16.9%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Lidocaine-Prilocaine Lidocaine/Prilocaine Brand 28 $1,799
Terbinafine Hcl Generic 30 $660
Diclofenac Sodium Generic 11 $638
Ketoconazole Generic 20 $289
Mupirocin Generic 21 $202
Allopurinol Generic 30 $189
Methylprednisolone Generic 13 $96
Cephalexin Generic 13 $42

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 12 billing codes

Paid by Medicare

$23,335

Medicare's payments for the services billed

Medicare patients

287

Average age 78

Services billed

546

138 women, 149 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 61%
Arthritis 49%
Ischemic heart disease 48%
Heart failure 35%
Chronic kidney disease 31%
Atrial fibrillation 29%
Depression 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

33 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record